MD Anderson Organizing Committee

Program Directors

Jose A. Karam, MD
Program Chairman
Associate Professor
Urology

Brian F. Chapin, MD
Program Co-Chairman
Associate Professor
Urology

Matthew T. Campbell, MD
Program Co-Chairman
Assistant Professor
Genitourinary Medical Oncology

Conference Committee

Ana Aparicio, MD
Associate Professor
Genitourinary Medical Oncology

Brian F. Chapin, MD
Program Co-Chairman
Associate Professor
Urology

Matthew T. Campbell, MD
Program Co-Chairman
Assistant Professor
Genitourinary Medical Oncology

Amishi Y. Shah, MD
Assistant Professor
Genitourinary Medical Oncology

Carol Fourtunia
Administrative Coordinator
Urology

John W. Davis, MD
Professor
Urology

Arlene O. Sieker-Radtke, MD
Associate Professor
Genitourinary Medical Oncology

Constance C. Tierney, CMP
Manager
CME/Conference Management

Neema Navai, MD
Assistant Professor
Urology

Christopher G. Wood, MD
Professor
Urology

Nizar M. Tannir, MD
Professor and Deputy Chairman
Genitourinary Medical Oncology

Christopher G. Wood, MD
Professor and Deputy Chairman
Urology

Curtis A. Pettaway, MD
Professor
Urology

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

PROGRAM

Friday, November 9, 2018

7:00 a.m. Registration and Continental Breakfast
7:50 Welcome and Opening Remarks
Jose A. Karam, MD
Brian F. Chapin, MD
Matthew T. Campbell, MD

SESSION I: Renal Cell Carcinoma
Moderator: Christopher G. Wood, MD

Management of the Incidental Small Renal Mass

8:00 Debate: What is the Role of Biopsy in the Management of the Small Renal Mass?
Mehrad Adibi, MD
Surena F. Matin, MD

8:30 Where Do We Stand With Genetic Screening for Familial Syndromes of RCC and Optimal Management of Patients With VHL?
Eric Jonasch, MD

Management of Locally Advanced Renal Cell Carcinoma

8:40 Management of Venous Involvement in Locally Advanced Renal Cell Carcinoma
Christopher G. Wood, MD

8:50 Debate: Adjuvant Therapy For Locally Advanced Renal Cell Carcinoma: Is It Ready for Prime Time?
Jose A. Karam, MD
Jeffrey J. Tomaszewski, MD

9:10 Questions and Answers
9:20 Break
Management of Metastatic Renal Cell Carcinoma

9:45 Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma? Nivolumab Plus Ipilimumab is the Best Front-Line Systemic Therapy
   Jianjun Gao, MD, PhD
   Cabozantinib is the Best Tyrosine Kinase Inhibitor and the Best Front-Line Systemic Therapy
   Jennifer Wang, MD
   Sunitinib or Pazopanib is the Best Front Line Systemic Therapy
   Matthew T. Campbell, MD

10:15 Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
   Yes
   Jose A. Karam, MD
   No
   Eric Jonasch, MD

10:40 Debate: What is the Best Salvage Therapy After Failure of Immune Checkpoint Inhibition?
   Cabozantanib
   TBD
   Axitinib
   Amado J. Zurita-Saavedra, MD
   Lenvatinib Plus Everolimus
   Amishi Y. Shah, MD

11:10 Systemic Therapy for Metastatic Non-Clear Cell Histology Patients: What Works and What Doesn’t?
   Pavlos Msouel, MD

11:20 Promising Emerging Systemic Therapies for Metastatic Renal Cell Carcinoma
   Nizar M. Tannir, MD

11:30 Questions and Answers

11:40 Case Presentations
   Moderator: Christopher G. Wood, MD
   Panel: Jianjun Gao, MD, PhD; Eric Jonasch, MD; Jose A. Karam, MD; Pavlos Msouel, MD; Amishi Y. Shah, MD; Amado J. Zurita-Saavedra, MD

12:05 p.m. Lunch (Provided)

SESSION II: Rare Genitourinary Cancers
   Moderator: Curtis A. Pettaway, MD

Penile Cancer

1:00 HPV and Penile Cancer: Pathogenesis, Prevention, Prognosis and Therapy
   Jad Chahoud, MD

1:20 Organ Preservation in Penile Cancer
   The Case for Surgery
   Curtis A. Pettaway, MD
   The Case for Radiation
   Karen E. Hoffman, MD

1:40 Robotic Assisted Inguinal Lymph Node Dissection: Ready for Prime Time?
   Mehrad Adibi, MD

1:50 Structured Case Discussions in Penile Cancer
   Moderator: Curtis A. Pettaway, MD
   Panel: Mehrad Adibi, MD; Jad Chahoud, MD; Karen E. Hoffman, MD; Shi-Ming Tu, MD

2:15 Break

Adrenal Tumors
   Moderator: Matthew T. Campbell, MD

2:35 Current Approach to Borderline Resectable ACC
   Jeffrey E. Lee, MD

2:45 Current Management of ACC and Future Directions
   Mouhammad A. Habra, MD

3:00 Updates in the Management of Malignant Pheochromocytoma/Paraganglioma
   Jeena M. Varghese, MD

3:15 Challenging Cases in Adrenal Tumors
   Moderator: Matthew T. Campbell, MD
   Panel: Mouhammad A. Habra, MD; Jeffrey E. Lee, MD; Jeena M. Varghese, MD

3:40 Indications, Approach, and Outcomes for Robotic RPLND
   John F. Ward, MD

3:50 What Can We Learn From Basket Studies About Treating Rare Tumors?
   Vivek Subbiah, MD

4:00 Andrew C. von Eschenbach Lecture Series
   Problems in the Diagnosis and Treatment of Prostate Cancer
   Urs E. Studer, MD

4:40 Distinguished Alumni Lectures
   Department of Urology
   David A. Swanson Distinguished Alumni Lecture Series
   What's So Exciting About BCG and Bladder Cancer?
   Robert Svatek, MD (Class of 2010)

   Department of GU Medical Oncology
   The Evolving Role of Epigenetics in Renal Cell Carcinoma
   Thai Ho, MD (Class of 2012)

5:30 p.m. Welcome Reception
## Saturday, November 10, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m.</td>
<td>Registration and Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td><strong>Welcome and Opening Remarks</strong></td>
<td>Jose A. Karam, MD; Brian F. Chapin, MD; Matthew T. Campbell, MD</td>
</tr>
<tr>
<td></td>
<td><strong>SESSION III: Bladder/Upper Tract Cancers</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Neema Navai, MD</td>
<td></td>
</tr>
<tr>
<td>8:05</td>
<td><strong>Superficial to Muscle-Invasive Bladder Cancer</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Options for Patients Failing BCG Therapy</strong></td>
<td>Ashish Kamat, MD</td>
</tr>
<tr>
<td>8:15</td>
<td><strong>Update in Robotic vs Open Radical Cystectomy – Where Do We Stand in 2018?</strong></td>
<td>Neema Navai, MD</td>
</tr>
<tr>
<td>8:25</td>
<td><strong>How to Make Orthotopic Bladder Substitution Work</strong></td>
<td>Urs E. Studer, MD</td>
</tr>
<tr>
<td>8:55</td>
<td><strong>Optimizing the Management of cT2N0 Disease</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>When Surgery Alone is Enough</td>
<td>Neema Navai, MD</td>
</tr>
<tr>
<td></td>
<td>When is Chemoradiation Appropriate?</td>
<td>Chad Tang, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Neoadjuvant Chemotherapy: A Risk Adaptive Approach</strong></td>
<td>Matthew T. Campbell, MD</td>
</tr>
<tr>
<td>9:25</td>
<td><strong>Molecular Characterization of Urothelial Carcinoma</strong></td>
<td>Seth Lerner, MD</td>
</tr>
<tr>
<td>9:40</td>
<td><strong>Challenging Surgical Cases</strong></td>
<td><strong>Moderator:</strong> Neema Navai, MD; <strong>Panel:</strong> Matthew T. Campbell, MD; Ashish Kamat, MD; Seth Lerner, MD; Chad Tang, MD</td>
</tr>
<tr>
<td>9:55</td>
<td><strong>Upper Tract Urothelial Carcinoma</strong></td>
<td><strong>Moderator:</strong> Surena F. Matin, MD</td>
</tr>
<tr>
<td>10:05</td>
<td><strong>Molecular Characterization of Upper Tract Urothelial Carcinoma</strong></td>
<td>Surena F. Matin, MD</td>
</tr>
<tr>
<td>10:15</td>
<td><strong>Neoadjuvant Strategies for Upper Tract Urothelial Carcinoma</strong></td>
<td>Amishi Y. Shah, MD</td>
</tr>
<tr>
<td>10:25</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>10:25</td>
<td><strong>Personalized Therapy is Here with FGFR3 Targeting Agents</strong></td>
<td>Arlene O. Siefker-Radtke, MD</td>
</tr>
<tr>
<td>10:35</td>
<td><strong>SESSION IV: Prostate Cancer</strong></td>
<td><strong>Moderator:</strong> Brian F. Chapin, MD</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>The Ideal Prostate Biopsy: Cost, Efficacy and Side Effects</strong></td>
<td>John W. Davis, MD</td>
</tr>
<tr>
<td>11:50</td>
<td><strong>Debate: Prostate Cancer Screening</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pro: MRI First</strong></td>
<td>Brian F. Chapin, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Con: Biopsy First</strong></td>
<td>Curtis A. Pettaway, MD</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>Early Disease</strong></td>
<td><strong>Moderator:</strong> John W. Davis, MD</td>
</tr>
<tr>
<td>12:20</td>
<td><strong>Debate</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pro: Focal Therapy for Prime Time</strong></td>
<td>Brian Miles, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Con: Focal Therapy for Research Only</strong></td>
<td>Ashely Ross, MD</td>
</tr>
<tr>
<td>12:20</td>
<td><strong>Ethics Lecture/Lunch (provided)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Physician Burnout – A Malignant Disease With an Innate Cure</strong></td>
<td>Naim El-Aswad, MD</td>
</tr>
<tr>
<td>1:00</td>
<td><strong>Cutting Edge of Radiation Therapy</strong></td>
<td><strong>Moderator:</strong> Seungtaek Choi, MD</td>
</tr>
<tr>
<td>1:20</td>
<td><strong>Brachytherapy</strong></td>
<td>Mitchell S. Anscher, MD</td>
</tr>
<tr>
<td>1:30</td>
<td><strong>Hypofractionated IMRT/Proton/SBRT in Localized PCa</strong></td>
<td>Chad Tang, MD</td>
</tr>
<tr>
<td>1:40</td>
<td><strong>Case Presentations</strong></td>
<td><strong>Moderator:</strong> Seungtaek Choi, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Panel:</strong> Mitchell S. Anscher, MD; Chad Tang, MD</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
</tbody>
</table>
High Risk Disease
Moderator: Louis L. Pisters, MD

2:10  Neoadjuvant System Therapy for Advanced PCa
      Brian F. Chapin, MD

2:20  Genetic Testing/Counseling in Localized and Metastatic Patients
      Ashley H. Woodson

2:30  Case Presentations
      Moderator: Louis L. Pisters, MD
      Panel: Brian F. Chapin, MD; Seungtaek Choi, MD; Eleni Efsthathiou, MD, PhD

Recurrent/Metastatic Disease
Moderator: Sumit K. Subudhi, MD, PhD

2:50  The Role of PET Imaging
      Aradhana M. Venkatesan, MD

3:00  An Update on the Treatment of M0 CRPC
      Ana Aparicio, MD

3:10  The Role of Immunotherapy in Prostate Cancer
      Sumit K. Subudhi, MD, PhD

3:20  Case Debates: PSA Recurrence
      Moderator: Ana Aparicio, MD
      Salvage Radiotherapy
      Seungtaek Choi, MD
      Systemic Therapy
      Eleni Efsthathiou, MD, PhD

3:40  Case Debates: Hormone Sensitive Metastatic Disease
      Moderator: Ana Aparicio, MD
      Abiraterone
      Amado J. Zurita-Saavedra, MD
      Docetaxel
      TBD

4:00 p.m.  Adjourn

MD Anderson Faculty

Mehrad Adibi, MD
Assistant Professor
Urology
Eric Jonasch, MD
Professor
Genitourinary Medical Oncology
Chad Tang, MD
Assistant Professor
Radiation Oncology

Mitchell S. Anscher, MD
Professor
Radiation Oncology
Ashish Kamat, MD
Professor
Urology
Nizar M. Tannir, MD
Professor and Deputy Chairman
Genitourinary Medical Oncology

Ana Aparicio, MD
Associate Professor
Genitourinary Medical Oncology
Jose A. Karam, MD
Associate Professor
Urology
Shi-Ming Tu, MD
Professor
Genitourinary Medical Oncology

Matthew T. Campbell, MD
Assistant Professor
Genitourinary Medical Oncology
Jeffrey E. Lee, MD
Professor & Chair
Surgical Oncology
Joena M. Varghese, MD
Assistant Professor
Endocrine Neoplasia & Hormonal Disorders

Jad Chahoud, MD
Fellow
Cancer Medicine
Surena F. Matin, MD
Professor
Urology
Aradhana M. Venkatesan, MD
Associate Professor
Radiology

Pavlos Msaouel, MD
Assistant Professor
Genitourinary Medical Oncology
Neema Navai, MD
Assistant Professor
Urology
Jennifer Wang, MD
Assistant Professor
Genitourinary Medical Oncology

Brian F. Chapin, MD
Associate Professor
Urology
Curtis A. Pettaway, MD
Professor
Urology
John F. Ward, MD
Professor
Urology

John W. Davis, MD
Professor
Urology
Christopher G. Wood, MD
Professor and Deputy Chairman
Urology

John L. Pisters, MD
Professor
Urology
Ashley H. Woodson
Sr. Genetic Counselor
Clinical Cancer Genetics

Amado J. Zurita-Saavedra, MD
Associate Professor
Genitourinary Medical Oncology

Eleni Efsthathiou, MD, PhD
Associate Professor
Genitourinary Medical Oncology
Arlene O. Siefker-Radtke, MD
Associate Professor
Genitourinary Medical Oncology

Jianjun Gao, MD, PhD
Assistant Professor
Genitourinary Medical Oncology
Amishi Y. Shah, MD
Assistant Professor
Genitourinary Medical Oncology

Mouhammad A. Habra, MD
Associate Professor
Endocrine Neoplasia & Hormonal Disorders
Vivek Subbiah, MD
Assistant Professor
Investigational Cancer Therapeutics

Karen E. Hoffman, MD
Associate Professor
Radiation Oncology
Sumit K. Subudhi, MD, PhD
Assistant Professor
Genitourinary Medical Oncology

Eric Jonasch, MD
Professor
Genitourinary Medical Oncology
Chad Tang, MD
Assistant Professor
Radiation Oncology

Nizar M. Tannir, MD
Professor and Deputy Chairman
Genitourinary Medical Oncology

Shi-Ming Tu, MD
Professor
Genitourinary Medical Oncology

Joena M. Varghese, MD
Assistant Professor
Endocrine Neoplasia & Hormonal Disorders

Aradhana M. Venkatesan, MD
Associate Professor
Radiology

Jennifer Wang, MD
Assistant Professor
Genitourinary Medical Oncology

John F. Ward, MD
Professor
Urology

Christopher G. Wood, MD
Professor and Deputy Chairman
Urology

Ashley H. Woodson
Sr. Genetic Counselor
Clinical Cancer Genetics

Amado J. Zurita-Saavedra, MD
Associate Professor
Genitourinary Medical Oncology